$1.2M COntract for NRIP - This stock is going crazy - March Top Stock Pick ************************************************************************** $1.2M COntract for NRIP - This stock is going crazy - March Top Stock Pick !!!!!!!!The Stock has VERY TIGHT FLOAT - ONLY 200 000 shares !!!!!! A few days ago NRIP reported January and February sales total more than $250,000.00, a 75% increase over the same period last year. ************************************************************************* Congratulations to all members who took advantage of our February Stock Pick GETC - The stock was profiled at 18 cents and reached 98 cents on Friday ************************************************************************* -------------------------------------------------- The hottest stock for the FIRST week of March NRIP - NRIP - NRIP - NRIP - NRIP ++ Top March Trading Alert ++ Company Profile Nutri Pharmaceuticals Research, Inc. Symbol: NRIP Current Price: $1.01 ONCE AGAIN - The Stock has VERY TIGHT FLOAT - ABOUT 200 000 shares SPECULATIVE NEAR TERM TARGET PRICE - $2.8 SPECULATIVE LONG TERM TARGET PRICE - $3.0 A few Reasons to own NRIP - Feb 24, 2004 NRIP announced the substantial increase of O2P(TM) orders January and February sales total more than $250,000.00, a 75% increase over the same period last year. - Feb 27, 2004 NRIP.PK is pleased to announce a new open-ended contract to supply high concentrate natural Vitamin E O2PT (oil to powder) product to International Specialty Botanical Products, Inc. This agreement is valued at minimum 1.2 million dollars This agreement is valued at minimum 1.2 million dollars This agreement is valued at minimum 1.2 million dollars - Their Facilities include • In-house research and development allow tailored formulations to your requirements • A granulator with a capacity of 500 kilos • A blender with a capacity of 800 kilos • 3 encapsulation machines capable of 75,000 capsules per hour • 4 tablet presses capable of a half million tablets per hour • Tablet coating is available • Transformation of liquids to powder (The O2P Process) • A complete bottling and packaging department -------------------READ READ READ---------------------- Nutri Pharmaceuticals Research, Inc. Announces 1.2 Million Dollar Sale ------------------------------------------------------- LAS VEGAS, Feb 27, 2004 (BUSINESS WIRE) -- Nutri Pharmaceuticals Research, Inc. (Pink Sheets:NRIP.PK), is pleased to announce a new open-ended contract to supply high concentrate natural Vitamin E O2PT (oil to powder) product to International Specialty Botanical Products, Inc. The contract calls for the monthly processing and shipment of two or more tons of Vitamin E powder. This agreement, valued at minimum 1.2 million dollars, will be a significant addition the company's yearly sales. "This contract, together with the recently announced acceptance of Kenko Corporation, of Tokyo, as our exclusive Japanese Distributor for the Company's O2PT products should further strengthen the Company's bottom line," Said Godfrey Yew, president and CEO of Nutri Pharmaceuticals Research. About Kenko: Kenco Corporation is a major Japanese manufacturer, distributor and world-wide exporter of chemicals, allied products, pharmaceuticals and supplementary nutrients. Last year it had global sales of 150 million dollars. About Nutri Pharmaceuticals Research Inc.: Nutri Pharmaceuticals Research Inc. is the world's leading processor of oil-to-powder. The company's proprietary O2P process transforms most edible oils into a free-flowing powder form that preserves more of the natural active components than other processes. Such powdered oils have application and demand in the food ingredient, livestock feeds, pet foods, nutraceutical, cosmetic and pesticide market sectors. We are also a wholesale private label manufacturer of vitamins and health food supplements. This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements can be identified by the lead-in "Looking Forward." These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements as a result of the effectiveness of management's strategies and implementation thereof. --------------- Disclaimer --------------- Please be advised that nothing within this email shall constitute a solicitation or an offer to buy or sell any security mentioned herein. This newsletter is neither a registered investment advisor nor affiliated with any broker or dealer. All statements made are our express opinion only and should be treated as such. We may own, buy and sell any securities mentioned at any time. This report includes forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements may include terms as "expect", "believe", "may", "will", "move","undervalued" and "intend" or similar terms. This newsletter was paid $700 from third party to send this report. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN ANY PROFILED COMPANY. To be removed from further emails send email to : --------------------- $1.2M COntract for NRIP - This stock is going crazy - March Top Stock Pick ************************************************************************** $1.2M COntract for NRIP - This stock is going crazy - March Top Stock Pick !!!!!!!!The Stock has VERY TIGHT FLOAT - ONLY 200 000 shares !!!!!! A few days ago NRIP reported January and February sales total more than $250,000.00, a 75% increase over the same period last year. ************************************************************************* Congratulations to all members who took advantage of our February Stock Pick GETC - The stock was profiled at 18 cents and reached 98 cents on Friday ************************************************************************* -------------------------------------------------- The hottest stock for the FIRST week of March NRIP - NRIP - NRIP - NRIP - NRIP ++ Top March Trading Alert ++ Company Profile Nutri Pharmaceuticals Research, Inc. Symbol: NRIP Current Price: $1.01 ONCE AGAIN - The Stock has VERY TIGHT FLOAT - ABOUT 200 000 shares SPECULATIVE NEAR TERM TARGET PRICE - $2.8 SPECULATIVE LONG TERM TARGET PRICE - $3.0 A few Reasons to own NRIP - Feb 24, 2004 NRIP announced the substantial increase of O2P(TM) orders January and February sales total more than $250,000.00, a 75% increase over the same period last year. - Feb 27, 2004 NRIP.PK is pleased to announce a new open-ended contract to supply high concentrate natural Vitamin E O2PT (oil to powder) product to International Specialty Botanical Products, Inc. This agreement is valued at minimum 1.2 million dollars This agreement is valued at minimum 1.2 million dollars This agreement is valued at minimum 1.2 million dollars - Their Facilities include • In-house research and development allow tailored formulations to your requirements • A granulator with a capacity of 500 kilos • A blender with a capacity of 800 kilos • 3 encapsulation machines capable of 75,000 capsules per hour • 4 tablet presses capable of a half million tablets per hour • Tablet coating is available • Transformation of liquids to powder (The O2P Process) • A complete bottling and packaging department -------------------READ READ READ---------------------- Nutri Pharmaceuticals Research, Inc. Announces 1.2 Million Dollar Sale ------------------------------------------------------- LAS VEGAS, Feb 27, 2004 (BUSINESS WIRE) -- Nutri Pharmaceuticals Research, Inc. (Pink Sheets:NRIP.PK), is pleased to announce a new open-ended contract to supply high concentrate natural Vitamin E O2PT (oil to powder) product to International Specialty Botanical Products, Inc. The contract calls for the monthly processing and shipment of two or more tons of Vitamin E powder. This agreement, valued at minimum 1.2 million dollars, will be a significant addition the company's yearly sales. "This contract, together with the recently announced acceptance of Kenko Corporation, of Tokyo, as our exclusive Japanese Distributor for the Company's O2PT products should further strengthen the Company's bottom line," Said Godfrey Yew, president and CEO of Nutri Pharmaceuticals Research. About Kenko: Kenco Corporation is a major Japanese manufacturer, distributor and world-wide exporter of chemicals, allied products, pharmaceuticals and supplementary nutrients. Last year it had global sales of 150 million dollars. About Nutri Pharmaceuticals Research Inc.: Nutri Pharmaceuticals Research Inc. is the world's leading processor of oil-to-powder. The company's proprietary O2P process transforms most edible oils into a free-flowing powder form that preserves more of the natural active components than other processes. Such powdered oils have application and demand in the food ingredient, livestock feeds, pet foods, nutraceutical, cosmetic and pesticide market sectors. We are also a wholesale private label manufacturer of vitamins and health food supplements. This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements can be identified by the lead-in "Looking Forward." These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements as a result of the effectiveness of management's strategies and implementation thereof. --------------- Disclaimer --------------- Please be advised that nothing within this email shall constitute a solicitation or an offer to buy or sell any security mentioned herein. This newsletter is neither a registered investment advisor nor affiliated with any broker or dealer. All statements made are our express opinion only and should be treated as such. We may own, buy and sell any securities mentioned at any time. This report includes forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements may include terms as "expect", "believe", "may", "will", "move","undervalued" and "intend" or similar terms. This newsletter was paid $700 from third party to send this report. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN ANY PROFILED COMPANY. To be removed from further emails send email to : ---------------------